Medicines **Optimisation intervention brief**

TITLE

Vagirux[®] 10mcg vaginal tablets for estradiol or Vagifem[®] 10mcg vaginal tablets (also known as 'inserts' or 'pessaries')

WHAT?

• For vaginal use, prescribe 10mcg Vagirux [®] in the form of vaginal tablets instead of
Vagifem [®] brand or estradiol generically.
WHY?
• Vagirux [®] 10mcg vaginal tablets contain the equivalent of estradiol 10mcg per tablet (as
estradiol hemihydrate) and are an alternative brand to Vagifem [®] 10mcg vaginal tablets.

- Both brands contain the same active ingredient (estradiol hemihydrate) but Vagirux® has a lower acquisition cost.
 - Vagifem[®] / estradiol pessaries = £16.72 for 24 (NHSBSA Drug Tariff Aug 21)
 Vagirux[®] = £11.34 for 24 (MIMS price Aug 21)
- Estradiol vaginal tablets should be prescribed by brand name Vagirux® (and not generically) to ensure the lower-acquisition cost product is supplied on an NHS prescription.
- Potential annual savings resulting from a brand switch across Hampshire Southampton and Isle of Wight CCG are in the order of £265K.

WHO?

- All appropriate patients currently prescribed Vagifem[®] or estradiol 10mcg vaginal tablets •
- Any new patients requiring vaginal tablets containing estradiol 10mcg •

TIPS?

- Community pharmacies should be notified prior to making the switch to ensure stocks • are available for the proposed changes.
- One pack of 24 Vagirux[®] 10mcg vaginal tablets contains one reusable applicator (can be used up to 24 times and should be disposed of when opening a new pack).
- Local trusts will continue to prescribe Vagifem[®], but are aware Vagirux[®] will be prescribed in primary care.

HOW?

- Use the provided clinical system search to identify all patients currently prescribed • Vagifem[®] or estradiol 10mcg vaginal tablets.
- Agree a process for switching patients with the practice. •
- Switch all appropriate patients to Vagirux[®] 10mcg vaginal tablets.
- Consider putting a reminder on the GP clinical system of the preferred formulary brand. SO WHAT?

Savings will be realised which can be reinvested for the benefit of patient care. •

FURTHER INFORMATION

- 1. https://www.medicines.org.uk/emc/product/11752
- 2. https://www.mims.co.uk/drugs/obstetrics-and-gvnaecology/menopausal
 - disorders/vagirux

Produced by South West Hampshire and North and Mid Hampshire Medicines Optimisation Teams for local use Date for review: Aug 2023 Date of preparation: Aug 2021